Craft

QIAGEN

Stock Price

€38.6

2024-10-29

Market Capitalization

€8.6 B

2024-10-29

Revenue

$2 B

FY, 2024

QIAGEN Summary

Company Summary

Overview
QIAGEN (formerly known as Diagen) is a company that provides sample technology solutions. Its products include genomic DNA extraction kits, exosome isolation devices, circulating tumor cells (CTCs), ribonucleic acid (RNA) tubes, centrifuges, etc. The company offers clinical analysis and interpretation, microbiome profiling, custom assay design, instrument integration, and other services. QIAGEN caters to the molecular biology research, pharmaceutical, biotech, technology, and industrial sectors.
Type
Public
Status
Active
Founded
1984
HQ
Venlo, NL | view all locations
Website
https://www.qiagen.com
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Thierry Bernard

    Thierry Bernard, Chief Executive Officer and Managing Director

  • Stephany Foster Spahr

    Stephany Foster Spahr, Senior Vice President, Head of Human Resources

  • Jonathan Sheldon

    Jonathan Sheldon, Senior Vice President, QIAGEN Digital Insights Business Area

  • Roland Sackers

    Roland Sackers, Chief Financial Officer and Managing Director

Operating MetricsView all

Customers

500K

FY, 2022

Products

500

FY, 2021

Institutional Investors

500K
83233.3%

FY, 2022

LocationsView all

49 locations detected

  • Venlo, LI HQ

    Netherlands

    Hulsterweg 82

  • Ann Arbor, MI

    United States

    1250 Eisenhower Pl

  • Beverly, MA

    United States

    100 Cummings Center #407J

  • Germantown, MD

    United States

    19300 Germantown Rd

  • Redwood City, CA

    United States

    1001 Marshall St #200

  • Clayton, VIC

    Australia

    1894 Dandenong Rd

and 43 others

QIAGEN Financials

Summary Financials

Revenue (Q1, 2025)
$483.5M
Gross profit (Q1, 2025)
$322.2M
Net income (Q1, 2025)
$90.8M
Cash (Q1, 2025)
$638.8M
EBIT (Q1, 2025)
$111.5M
Enterprise value
$9.4B

Footer menu